Every 8-K that Veracyte, Inc. (VCYT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow VCYT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VCYT filings page.
Veracyte, Inc. reported total revenue of $150.3 million for the quarter ended June 30, 2026, up 15% from $130.2 million a year earlier. Testing revenue grew 19% to $145.7 million, driven by Decipher prostate testing revenue of $91.9 million and Afirma revenue of $51.2 million. Test volumes increased 13% to 50,967, including 17% growth in Decipher tests to about 29,700 and 10% growth in Afirma tests to about 18,600.
GAAP net income was $25.5 million, a 17.0% margin and an improvement from a prior-year loss, with diluted EPS of $0.31. Non-GAAP gross margin rose to 75% and adjusted EBITDA reached $44.0 million, or 29.2% of revenue. The company generated $45.8 million of operating cash flow and ended the quarter with $485.2 million in cash, cash equivalents and short-term investments.
Management highlighted launches of the Prosigna Breast Test and the TrueMRD Monitoring Test for muscle-invasive bladder cancer, along with Medicare coverage for TrueMRD. Veracyte raised its 2026 total revenue outlook to $590–$596 million and testing revenue guidance to $576–$582 million, and continues to expect adjusted EBITDA margin above 26%.
Veracyte, Inc. reported the results of its 2026 annual meeting of stockholders, where shareholders approved an amendment to the company’s 2023 Equity Incentive Plan. The amendment increases the shares of common stock reserved for issuance under the plan by 3,500,000 shares.
All nine director nominees were elected to serve until the 2027 annual meeting. Stockholders also ratified Ernst & Young LLP as independent registered public accounting firm for 2026 and approved, on a non-binding advisory basis, the compensation of the company’s named executive officers and the 2023 Plan Amendment.
Veracyte reported strong first-quarter 2026 results with higher growth and profitability. Total revenue rose 21% to $139.1 million, led by testing revenue of $135.1 million, up 26%, driven by Decipher revenue of $86.5 million and Afirma revenue of $46.4 million.
Profitability improved significantly. GAAP net income was $28.7 million, or 20.6% of revenue, compared with $7.0 million a year earlier, and adjusted EBITDA reached $42.8 million, or 30.8% of revenue. Cash from operations was $35.2 million, and Veracyte ended March 31, 2026 with $439.1 million in cash, cash equivalents and short-term investments.
Management also raised its 2026 outlook. The company now guides total revenue to $582 million–$592 million and testing revenue to $570 million–$580 million, and expects adjusted EBITDA margin to exceed 26%, reflecting confidence in growth from its cancer diagnostic tests and upcoming product launches.
Veracyte, Inc. appointed Dr. Kevin Haas, 40, as Chief Development and Technology Officer, effective March 24, 2026. He previously served as Chief Technology Officer and in senior technology and bioinformatics roles at Myriad Genetics and its women’s health business.
Under his offer letter dated March 13, 2026, Dr. Haas will receive an initial annual base salary of $500,000 and will be eligible for an annual performance-based cash bonus targeted at 55% of eligible annual earnings, with his 2026 bonus prorated based on his start date.
He is also slated to receive a restricted stock unit award with a target value of $1,500,000 vesting over four years and a performance-based restricted stock unit award with a target value of $1,500,000, subject to performance objectives and continued service, all under Veracyte’s 2023 Equity Incentive Plan.
Veracyte reported strong fourth quarter and full-year 2025 results with double-digit growth and higher profitability. Q4 total revenue rose 19% to $140.6 million, with testing revenue up 21% to $135.8 million and Decipher and Afirma driving growth. Q4 GAAP net income reached $41.1 million, or 29.3% of revenue, and adjusted EBITDA was $42.3 million, or 30.1% of revenue, while operating cash flow was $52.6 million.
For 2025, total revenue increased 16% to $517.1 million and testing revenue grew 18% to $493.2 million. Full-year GAAP net income grew 175% to $66.4 million, with adjusted EBITDA up 55% to $142.5 million, or 27.6% of revenue, and operating cash flow of $136.3 million, ending the year with $412.9 million in cash, cash equivalents and short-term investments. Veracyte reiterated 2026 guidance for 10%–13% total revenue growth to $570–$582 million and expects adjusted EBITDA margin of approximately 25%.
Veracyte, Inc. reported preliminary, unaudited estimates for the fourth quarter and full year ended December 31, 2025. For the fourth quarter, it expects total revenue between $138 million and $140 million, testing revenue between $134 million and $136 million, and testing volume of approximately 45,500 tests. For the full year 2025, Veracyte expects total revenue between $515 million and $517 million, testing revenue between $491 million and $493 million, and testing volume of approximately 169,700 tests. The company also expects to report an adjusted EBITDA margin of greater than 25% for the full year. These figures are preliminary and may change after completion of year-end closing procedures and the audit of the financial statements.
Veracyte, Inc. furnished an 8-K announcing financial results for the quarter ended September 30, 2025. The results are provided in a press release attached as Exhibit 99.1.
The company states this information, including Exhibit 99.1, is furnished and not deemed “filed” under Section 18 of the Exchange Act, and is not incorporated by reference unless specifically so stated.
Veracyte, Inc. (VCYT) filed an 8-K to disclose the voting results of its 17 June 2025 Annual Meeting and related governance actions. Stockholders elected all seven director nominees with support levels ranging from 93.8% to 98.3% of votes cast (excluding broker non-votes). Ernst & Young LLP was ratified as independent auditor for FY-2025 with 99.7% approval.
A key item was a 2.5 million-share increase to the 2023 Equity Incentive Plan. The amendment passed with 72.6% of votes cast (50.6 m For, 19.1 m Against). Assuming full issuance, potential dilution equals roughly 3.4% of the 73.3 million shares outstanding reported in the company’s February 2025 10-K. While the plan expansion strengthens Veracyte’s ability to attract and retain talent in a competitive diagnostics market, it also modestly dilutes existing holders.
Shareholders backed executive compensation in a non-binding “say-on-pay” vote (97.3% approval) and endorsed an annual frequency for future say-on-pay votes (96.2% choosing one-year cadence). The Board has adopted this schedule until at least the 2031 meeting.
Overall, the meeting reinforced management’s governance platform, maintained auditor continuity, and provided additional equity capacity. No immediate financial results or operational updates were included; therefore, market impact is likely limited to perceptions around future dilution and compensation alignment.